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Volume 53, Number 5 Abstracts 1449have concomitant DVT (Bradley MJ, et al; Clin Radiol 1995;50:232-4).
The significance of finding DVT and PE at the time of presentation of PE is
debated. Some studies note that diagnosis of proximal DVT is an indepen-
dent predictor of adverse outcome. Other studies have not confirmed these
findings (Wicki J, et al; Thromb Haemost 2000;84:548-52 and Girard P et
al; Chest 2005;128:1593-600). This study aimed to assess the association
between a concurrent diagnosis of DVT and PE on risk of death in patients
with a first objectively confirmed diagnosis of acute symptomatic PE. The
primary end point of this prospective cohort study of outpatients was all
cause mortality, and the secondary outcome was PE-specific death in the first
3 months after the PE diagnosis. PE was diagnosed in 707 patients, and
DVT was also diagnosed in 362 (51.2%); 77 patients (10.9%) died during
follow-up. Patients with concurrent DVT had increased all-cause mortality
(adjustedHR, 2.05; 95%CI, 1.24-3.38, P .005) and increased PE-specific
mortality (adjusted HR 4.25; 95% CI, 1.61-11.25, P  .04). An external
validation cohort of 4476 patients with acute PE enrolled in the RIETE
registry also determined a concurrent DVT diagnosed at the time of PE was
a significant predictor of all-cause (adjusted HR, 1.66; 95% CI, 1.28-2.15;
P  .001) and PE-specific mortality (HR, 2.01; 95% CI, 1.18-3.44,
P  .01).
Comment: These data provide evidence that a first episode of acute
symptomatic PE with a concurrent diagnosis of DVT imparts increased risk
of all-cause and PE-specific death in the first 3 months after a diagnosis of
PE. Although some may argue that a patient with a diagnosed PE does not
need investigation for lower extremity DVT because the PE is going to be
treated with anticoagulation anyway, the data imply patients with PE should
undergo investigation for DVT for prognostic purposes and risk stratifica-
tion. Such studies may identify patients at high risk of early death who may
benefit from more intensive surveillance or aggressive therapy.
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Conclusion: Caffeine increases walking distance, maximum strength,
and endurance in patients with moderate intermittent claudication but
adversely affects balance.Summary: Pharmacologic agents may modestly improve walking dis-
tance in patients with intermittent claudication, and statins may be the most
s
fffective drugs for this purpose (Momsen AH, et. al; Eur J Vasc Endovasc
urg 2009;38:463-74). Caffeine, the widely consumed central nervous
ystem stimulant, appears also to have potentially favorable effects on exer-
ise and endurance. Caffeine increases endurance in young people when they
xercise at 60% to 85% of maximum oxygen uptake (Graham TE, Sports
ed 2001;31:785-807). Submaximal isometric contraction is also im-
roved, and the rate of perceived exertion during exercise is decreased with
affeine (Falk B, Eur J Appl Physiol Occup Physiol 1989;59:168-73). In
ddition, caffeine has positive effects on cycling endurance and perceived
xertion in healthy elderly people (Norager CB, et al; Clin Endocrinol (Oxf)
006;65:223-8). The authors therefore postulated caffeine might be an
ffective drug to increase walking distance in patients with intermittent
laudication. They performed a randomized, double-blind, placebo-con-
rolled crossover study of 88 patients recruited from outpatient clinics.
articipants abstained from caffeine for 48 hours before each test and then
eceived oral caffeine (6 mg/kg) or a placebo. After 75 minutes, pain-free
nd maximum walking distance on a treadmill, perceived pain, reaction
imes, isometric knee extension strength, submaximal knee extension endur-
nce, cognitive function, and postural stability were measured. Analysis was
y intention to treat.
Caffeine increased pain-free walking distance by 20.0% (95% CI, 3.7%-
8.8%, P  .014). increased maximum walking distance by 26.6% (95% CI,
2.1%-43.0%; P  .001), increased muscle strength by 9.8% (95% CI,
.0-17.0%; P  .005), and increased endurance by 21.4% (95% CI, 1.2%-
5.7%, P  .004). There were no changes in reaction time or cognition.
ostural stability, however, was significantly reduced by 22.1% (95% CI,
1.7%-33.4%, P .001) with eyes open and by 21.8% (95%CI, 7.6%-37.8%,
P  .002) with eyes closed .
Comment: The effects of caffeine on intermittent claudication seems
imilar to those after the administration of lipid-lowering agents and exceed
hose reported in trials of various other agents, such as pentoxifylline.
ecommendation of a drug to improve intermittent claudication, however,
hould not be based simply on increases in walking distance but rather on
mprovements in quality of life. Studies addressing caffeine consumption
ver time in conjunction with assessment by quality of life instruments are
eeded to judge the true potential impact of caffeine on quality of life in
atients with intermittent claudication. In addition, the adverse effect of
affeine on balance is worrisome in an elderly population where falls are a
ignificant source of morbidity and mortality. The study had multiple
unding sources, but Starbucks was not among the study sponsors!
